RT Journal Article
SR Electronic
T1 Hepatitis E in Bangladesh: Insights from a National Serosurvey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.14.21258872
DO 10.1101/2021.06.14.21258872
A1 Andrew S Azman
A1 Kishor Kumar Paul
A1 Taufiqur Rahman Bhuiyan
A1 Aybüke Koyuncu
A1 Henrik Salje
A1 Firdausi Qadri
A1 Emily S Gurley
YR 2021
UL http://medrxiv.org/content/early/2021/06/18/2021.06.14.21258872.abstract
AB Background Hepatitis E virus, typically genotypes 1 and 2, is a major cause of avoidable morbidity and mortality in South Asia. Although case fatality risk among pregnant women can reach as high as 25%, a lack of population-level disease burden data has been cited as a primary factor in key global policy recommendations against the routine use of licensed hepatitis E vaccines, one of the only effective tools available for preventing disease and death.Methods We tested serum from a nationally-representative serosurvey in Bangladesh for anti-HEV IgG. We estimated the proportion of the population with evidence of historical HEV infection and used Bayesian geostatistical models to generate high-resolution national maps of seropositivity. We examined variability in seropositivity by individual-level, household-level, and community-level risk factors using spatial logistic regression.Results We tested serum samples from 2924 individuals from 70 communities representing all divisions of Bangladesh and estimated a national seroprevalence of hepatitis E of 20% (95% CI 17-24%). Seropositivity increased with age and male sex (OR: 2.2, 95% CI: 1.8–2.8). Community-level seroprevalence ranged from 0-78% with the seroprevalence in urban areas being higher, including Dhaka, the capital, with 3-fold (95%CrI 2.3-3.7) higher seroprevalence than the rest of the country.Conclusion Hepatitis E infections are common throughout Bangladesh, though 90% of women reach reproductive age without any evidence of previous exposure to the virus, thus likely susceptible to infection and disease. Strengthening clinical surveillance for hepatitis E, especially in urban areas may help generate additional evidence needed to appropriately target interventions like vaccines to the populations most likely to benefit.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe original data collection was supported by the Centers for Disease Control and Prevention (5U01GH001207-02). icddr,b acknowledges the commitment of the US CDC to its research efforts and thanks the Governments of Bangladesh, Canada, Sweden, and the UK for providing core or unrestricted support. US National Institutes for Health (NIH; R01 AI135115 ASA). Support to FQ and her laboratory also came from the NIH Fogarty International Center (TW005572) and Emerging Global Leader Award (K43 TW010362). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the icddr,b ethics review board (protocol number PR-14058); this secondary analysis was reviewed and deemed exempt from review by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board. All adult participants provided written informed consent to participate in the study. Parents or guardians of all child participants provided written informed consent on their behalf.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and source code to reproduce analyses are available at https://github.com/HopkinsIDD/hepE-bangladesh-national-serosurvey. https://github.com/HopkinsIDD/hepE-bangladesh-national-serosurvey